Black Diamond Therapeutics
BDTX
113 hedge funds and large institutions have $705M invested in Black Diamond Therapeutics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 20 closing their positions.
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
4% more funds holding
Funds holding: 109 → 113 (+4)
1.42% more ownership
Funds ownership: 79.37% → 80.79% (+1.4%)
9% less call options, than puts
Call options by funds: $1.2M | Put options by funds: $1.32M
23% less capital invested
Capital invested by funds: $915M → $705M (-$210M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.2M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$22.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.44M |
| 5 |
Axa
Paris,
France
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$15M |
| 3 |
Jennison Associates
New York
|
-$11.7M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$10.5M |
| 5 |
CC
Casdin Capital
New York
|
-$9.28M |
BDTX Hedge Fund Activity: Q1 2021 in Review
113 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2021, worth a combined $705M — down 23% from $915M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BDTX positions and 20 closed out — a net gain of 4 holders — while 36 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $26.2M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $19.4M sold.
- 113 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2021, up from 109 in Q4 2020.
- Funds reported $705M of Black Diamond Therapeutics stock for Q1 2021, down 23% quarter-over-quarter.
- 24 funds opened new Black Diamond Therapeutics positions in Q1 2021 and 20 closed out, a net change of +4 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2021 was State Street, an estimated $26.2M added.
- The largest Black Diamond Therapeutics seller in Q1 2021 was Point72 Asset Management, an estimated $19.4M sold.
Based on aggregated 13F filings for Q1 2021.